Point72 (DIFC)’s Lineage Cell Therapeutics LCTX Stock Holding History

Point72 (DIFC)’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11,400	Closed	-$10.3K	–	1551
2025 Q2	$10.3K	Buy	+11,400	New	+$6.76K	﹤0.01%	1315

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 (DIFC)'s LCTX Position: Q3 2025 in Review

Point72 (DIFC) sold out of Lineage Cell Therapeutics (LCTX) in Q3 2025, closing a stake of 11,400 shares — an estimated $10.3K sold.

Point72 (DIFC) first reported a position in LCTX in Q2 2025 and held it in 1 quarter. The position peaked at $10.3K in Q2 2025. 112 funds tracked by Wall St. Rank hold LCTX as of Q3 2025.

Point72 (DIFC) reported no remaining Lineage Cell Therapeutics position as of Q3 2025 after selling out during the quarter.
Point72 (DIFC) sold 11,400 Lineage Cell Therapeutics shares in Q3 2025, an estimated $10.3K.
Point72 (DIFC) first reported a position in Lineage Cell Therapeutics in Q2 2025 and held it in 1 quarter.
Point72 (DIFC)'s Lineage Cell Therapeutics position peaked at $10.3K in Q2 2025.
112 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.